Literature DB >> 11918691

Identification of broadly recognized, T helper 1 lymphocyte epitopes in an equine lentivirus.

Darrilyn G Fraser1, J Lindsay Oaks, Wendy C Brown, Travis C McGuire.   

Abstract

Equine infectious anaemia virus (EIAV) is a horse lentivirus causing lifelong, persistent infection. During acute infection, CD8(+) cytotoxic T lymphocytes (CTL) are probably involved in terminating plasma viraemia. However, only a few EIAV CTL epitopes, restricted to fewer horse major histocompatibility complex (MHC) class I alleles, are known. As interferon-gamma (IFN-gamma)-secreting CD4(+), T helper 1 (Th1) lymphocytes promote CTL activity and help maintain memory CTL, identifying broadly recognized EIAV Th1 epitopes would contribute significantly to vaccine strategies seeking to promote strong CTL responses among horses with varying class I haplotypes. To this end, peripheral blood mononuclear cells (PBMC) from 10 MHC disparate, EIAV-infected horses were tested in T-lymphocyte proliferation assays for recognition of peptides from the Gag p26 capsid region and a portion of Pol. Both regions are highly conserved among EIAV isolates, and this Pol region is 51-63% homologous to other lentiviral Pol proteins. Seven of 10 horses recognized peptide Gag 221-245, and peptides Gag 242-261 and Pol 323-344 were recognized by five and four horses, respectively. Furthermore, the Gag peptides were recognized by two additional horses after resolving their initial plasma viraemia, indicating that these two peptides can be immunodominant early in infection. Gag peptide-responsive PBMC produced only IFN-gamma, indicating a Th1 response, while Pol 323-344-responsive PBMC produced IFN-gamma both with and without interleukin-4. PBMC from uninfected horses failed to either proliferate or secrete cytokines in response to peptide stimulation. Finally, CD4(+) T lymphocytes were required for proliferation responses, as shown by assays using CD4- versus CD8-depleted PBMC.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11918691      PMCID: PMC1782660          DOI: 10.1046/j.0019-2805.2001.01370.x

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  43 in total

1.  Tissue sites of persistent infection and active replication of equine infectious anemia virus during acute disease and asymptomatic infection in experimentally infected equids.

Authors:  S M Harrold; S J Cook; R F Cook; K E Rushlow; C J Issel; R C Montelaro
Journal:  J Virol       Date:  2000-04       Impact factor: 5.103

2.  Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes.

Authors:  J E Schmitz; M J Kuroda; S Santra; V G Sasseville; M A Simon; M A Lifton; P Racz; K Tenner-Racz; M Dalesandro; B J Scallon; J Ghrayeb; M A Forman; D C Montefiori; E P Rieber; N L Letvin; K A Reimann
Journal:  Science       Date:  1999-02-05       Impact factor: 47.728

3.  Containment of simian immunodeficiency virus infection: cellular immune responses and protection from rechallenge following transient postinoculation antiretroviral treatment.

Authors:  J D Lifson; J L Rossio; R Arnaout; L Li; T L Parks; D K Schneider; R F Kiser; V J Coalter; G Walsh; R J Imming; B Fisher; B M Flynn; N Bischofberger; M Piatak; V M Hirsch; M A Nowak; D Wodarz
Journal:  J Virol       Date:  2000-03       Impact factor: 5.103

4.  Antigenic drift of equine infectious anemia virus in chronically infected horses.

Authors:  Y Kono; K Kobayashi; Y Fukunaga
Journal:  Arch Gesamte Virusforsch       Date:  1973

5.  Viremia and immunological responses in horses infected with equine infectious anemia virus.

Authors:  Y Kono
Journal:  Natl Inst Anim Health Q (Tokyo)       Date:  1969

6.  Immunization with live attenuated simian immunodeficiency virus induces strong type 1 T helper responses and beta-chemokine production.

Authors:  M C Gauduin; R L Glickman; S Ahmad; T Yilma; R P Johnson
Journal:  Proc Natl Acad Sci U S A       Date:  1999-11-23       Impact factor: 11.205

7.  Antigenic variation during persistent infection by equine infectious anemia virus, a retrovirus.

Authors:  R C Montelaro; B Parekh; A Orrego; C J Issel
Journal:  J Biol Chem       Date:  1984-08-25       Impact factor: 5.157

8.  Recrudescence of equine infectious anemia by treatment with immunosuppressive drugs.

Authors:  Y Kono; K Hirasawa; Y Fukunaga; T Taniguchi
Journal:  Natl Inst Anim Health Q (Tokyo)       Date:  1976

9.  Independent regulation of lymphocytic choriomeningitis virus-specific T cell memory pools: relative stability of CD4 memory under conditions of CD8 memory T cell loss.

Authors:  S M Varga; L K Selin; R M Welsh
Journal:  J Immunol       Date:  2001-02-01       Impact factor: 5.422

10.  Transmission of equine infectious anemia virus from horses without clinical signs of disease.

Authors:  C J Issel; W V Adams; L Meek; R Ochoa
Journal:  J Am Vet Med Assoc       Date:  1982-02-01       Impact factor: 1.936

View more
  4 in total

1.  Selecting peptides to optimize Th1 responses to an equine lentivirus using HLA-DR binding motifs and defined HIV-1 Th peptides.

Authors:  Darrilyn G Fraser; Robert H Mealey; Travis C McGuire
Journal:  Immunogenetics       Date:  2003-08-27       Impact factor: 2.846

2.  Lymphocyte proliferation responses induced to broadly reactive Th peptides did not protect against equine infectious anemia virus challenge.

Authors:  Darrilyn G Fraser; Steve R Leib; Bao Shan Zhang; Robert H Mealey; Wendy C Brown; Travis C McGuire
Journal:  Clin Diagn Lab Immunol       Date:  2005-08

3.  Envelope determinants of equine infectious anemia virus vaccine protection and the effects of sequence variation on immune recognition.

Authors:  Tara L Tagmyer; Jodi K Craigo; Sheila J Cook; Deborah L Even; Charles J Issel; Ronald C Montelaro
Journal:  J Virol       Date:  2008-01-30       Impact factor: 5.103

4.  Experimental Rhodococcus equi and equine infectious anemia virus DNA vaccination in adult and neonatal horses: effect of IL-12, dose, and route.

Authors:  R H Mealey; D M Stone; M T Hines; D C Alperin; M H Littke; S R Leib; S E Leach; S A Hines
Journal:  Vaccine       Date:  2007-08-15       Impact factor: 3.641

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.